Develops oral therapies for diabetes and other metabolic and inflammatory diseases, including cadisegliatin as an add-on to insulin for people with diabetes.
10-K for FY2025, filed Mar 10, 2026
Pharmaceutical partners license drug candidates and may collaborate on their development; academic partners also work with the company on research and development.
10-K for FY2025, filed Mar 10, 2026In addition to our clinical development program for cadisegliatin, we continue to advance the research and development of our other…View ↗
Seeking additional strategic collaborations and additional funding to support the continued development and commercialization of our…View ↗
We also continue to seek strategic collaborations with other pharmaceutical companies, such as our partnerships with Cantex and Newsoara…View ↗
Broader cadisegliatin trials
The latest report describes an ongoing cadisegliatin trial for diabetes and adds a separate study in insulin-dependent people with diabetes; the older report described pivotal studies as planned.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 10, 2026In December 2025, together with our partner G42 Investments AI Holding RSC Ltd. (“G42 Investments”), we initiated a double-blind…View ↗
In the second quarter of 2025 we resumed our Phase 3 CATT1 trial. The CATT1 trial is a double-blind, randomized trial to assess the effect…View ↗
In December 2025, we and our partner, G42 Investments, initiated a double-blind randomized controlled Phase 2 trial in the Middle East…View ↗
Competes with Zucara Therapeutics, Diasome Pharmaceuticals, Lexicon Pharmaceuticals, Adocia, Sanofi, Vertex Pharmaceuticals, and Eli Lilly
10-K for FY2025, filed Mar 10, 2026Adjunctive non-insulin pharmacotherapies and hypoglycemia-focused approaches. Multiple companies are developing agents intended to improve…View ↗
Loading...